Aberrant expression of ERG promotes resistance to combined PI3K and AR pathway inhibition through maintenance of AR target genes

Based on our previous work defining the molecular rationale for combined targeting of the PI3K and AR pathways in PTEN loss prostate cancer, the first clinical trial was recently reported demonstrating a significant benefit for combination therapy in patients with metastatic prostate cancer. In this...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Mol Cancer Ther
Hoofdauteurs: Mao, Ninghui, Gao, Dong, Hu, Wenhuo, Hieronymus, Haley, Wang, Shangqian, Lee, Young Sun, Lee, Cindy, Choi, Danielle, Gopalan, Anuradha, Chen, Yu, Carver, Brett S
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726496/
https://ncbi.nlm.nih.gov/pubmed/31296553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-1386
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items